C12N 2795/10042
Virus or viral particle as vehicle
Official title: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N2795/10042 (Virus or viral particle as vehicle) appears on 8 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 11
- Assignees
- 10
- Inventors
- 20
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Production and functionalization of nanoparticles derived from phage T5 and therapeutic uses13 Jan 2026US 12,521,432 B2Centre National de la Recherche Scientifique (CNRS)
- Compositions and methods for activating silent gene clusters4 Apr 2023US 11,618,898 B2Zymergen Inc.
- Theragnostic particles18 Feb 2020US 10,562,938 B2The Regents of the University of Colorado, a body corporate
- Compositions and methods for activating silent gene clusters2 Jul 2019US 10,336,999 B2Zymergen Inc.
- Theragnostic particles19 Sep 2017US 9,765,122 B2University of Washington through its Center for Commercialization
- Systems for modulating drug metabolism by cells, methods and compositions thereof13 Mar 2025US 2025/0084398 A1
- Production and functionalization of nanoparticles derived from phage t5 and therapeutic uses22 Jun 2023US 2023/0190925 A1Centre National de la Recherche Scientifique (CNRS)
- Engineered bacteriophage t4 nanoparticles as a potential targeted activator of hiv-1 latency in cd4+ human t-cells26 Jan 2023US 2023/0026666 A1The Catholic University of America
- Anti-crispr inhibitors4 Aug 2022US 2022/0243213 A1The Governing Council of the University of Toronto
- Compositions and methods for activating silent gene clusters5 Sep 2019US 2019/0270986 A1Zymergen Inc.
Most cited
By later US patents
- Compositions and methods for activating silent gene clusters1US 10,336,999 B2Zymergen Inc. · 2019
- Protein and nucleic acid delivery vehicles, components and mechanisms thereof1US 8,802,418 B2The Catholic University of America · 2014
- Theragnostic particles1US 9,765,122 B2University of Washington through its Center for Commercialization · 2017